AI Unites OR and Recovery to Combat Deadly Surgical Leaks

STRASBOURG, France and KITCHENER, ON – May 01, 2026 – Two medical technology firms are joining forces to bridge a dangerous and costly gap in surgical care, creating a digital thread that connects the operating room to the patient’s bedside. Qaelon Medical, a French innovator in surgical technology, and FluidAI Medical, a Canadian leader in post-operative recovery intelligence, have announced a strategic collaboration to build a unified data ecosystem. Their target is one of surgery's most feared complications: the anastomotic leak.

For the first time, this partnership aims to link real-time data from the moment a surgeon creates an intestinal connection to the continuous monitoring of how that connection heals in the days that follow. By creating this seamless flow of information, the companies hope to transform the fight against a problem that has plagued gastrointestinal surgery for decades, moving from reactive crisis management to proactive, data-driven prevention.

The High Cost of a Stubborn Complication

Anastomosis, the surgical rejoining of two hollow structures like the intestine, is a common procedure. When it fails, the resulting leak can be catastrophic. Despite advances in surgical techniques, the incidence of anastomotic leaks (AL) remains stubbornly high, affecting up to 30% of patients in high-risk procedures. The consequences are severe for patients and healthcare systems alike.

Mortality rates can skyrocket, reaching as high as 16.4% in cases of rectal anastomosis. Patients who survive a leak face a grueling recovery, with hospital stays extended by 2.4 to 5.3 times compared to uncomplicated cases. The financial toll is staggering; treating a single leak can add over $72,000 to a patient's bill, nearly tripling the cost of a standard recovery. The global market for devices to address this issue reflects the scale of the problem, valued at over $3.4 billion in 2025 and projected to grow steadily.

The core challenge is that leaks are often detected late, typically after a patient shows clear signs of clinical decline like fever or sepsis. By then, intervention is more complex and outcomes are significantly worse. This collaboration seeks to replace delayed, subjective assessments with early, objective data.

A Two-Part Solution to a Continuous Problem

The partnership combines two distinct but complementary technologies, each addressing a different phase of the patient's journey.

Inside the operating room, Qaelon Medical is developing a platform to digitize what has historically been a subjective process. Surgeons currently test a new anastomosis for leaks using methods like filling the cavity with saline and looking for air bubbles—a technique that relies heavily on visual inspection and experience. Qaelon’s system, currently in development, aims to replace this with an objective, physiologic signal. By using advanced insufflation and real-time detection, it generates quantifiable data on the integrity of the surgical closure at the moment of its creation. This data can be seamlessly documented in the electronic health record (EHR), creating a permanent, objective baseline of the procedure's success.

Once the patient moves to recovery, FluidAI Medical’s technology takes over. The company’s Recovery Intelligence and Surgical Excellence (RISE) Program is a commercially available suite of tools centered on the Origin™ device. This FDA-cleared sensor provides continuous, real-time monitoring of a patient's surgical drainage fluid directly at the bedside. It analyzes biochemical markers that can signal a developing complication hours or even days before a patient feels sick. This data feeds into Stream Care™, an AI-powered platform that analyzes trends, integrates with EHR data, and flags high-risk patients for clinicians, enabling earlier and more precise intervention.

From Siloed Data to Surgical Intelligence

Separately, each technology offers a significant advance. Together, they promise a paradigm shift. The collaboration's goal is to create a closed loop where data from the OR directly informs post-operative monitoring, giving clinicians a level of context that has never existed before.

"As surgery becomes increasingly data-enabled, the future will be defined by ecosystems built on objective physiologic data," said Liam Burns, CEO of Qaelon Medical, in the announcement. "Through our collaboration with FluidAI, we expect to accelerate clinical evidence generation and more precisely quantify outcomes and economic value - moving from data capture to true surgical intelligence."

An objective signal from Qaelon’s device indicating a perfect seal in the OR could be correlated with data from FluidAI’s Origin monitor during recovery. Over time, the combined dataset could train AI models to understand the subtle healing patterns that differentiate a successful recovery from an impending leak. This could help predict which patients are at highest risk based not just on pre-operative factors, but on the specifics of their actual surgery.

"The next frontier in surgical care is connecting data across the full perioperative journey, not just capturing it in isolated moments," noted Youssef Helwa, CEO of FluidAI Medical. "Qaelon is doing pioneering work in intraoperative leak detection and connecting that signal to what we observe during recovery could give clinicians a level of context that simply hasn't existed before."

Dr. Eran Shlomovitz, Chief Medical Officer of Qaelon Medical, emphasized the clinical need. "By creating a quantitative physiologic signal in the operating room and extending that into post-operative monitoring, we can begin to close one of the most critical gaps in surgical care," he stated.

Navigating the Market and Regulatory Landscape

While the vision is ambitious, the collaboration is still in its early stages. Qaelon Medical’s platform is under development and has not yet been cleared for commercial sale in the United States or Europe. The integrated system envisioned by the partnership will require its own extensive clinical validation and regulatory review before it can become a clinical reality.

FluidAI Medical, however, has already established a commercial foothold. Its Origin™ device received FDA 510(k) clearance in 2025 and is also cleared for use in Canada and Saudi Arabia. The company has been conducting trials across four continents and has reported positive feedback from limited market releases, with care teams detecting leaks earlier. It is important to note that while the Origin hardware is cleared in the US, the company's specific AI-driven algorithm for anastomotic leak prediction is not yet available there, highlighting the complex, jurisdiction-by-jurisdiction nature of medical software regulation.

Over time, the companies plan to work with clinicians and research institutions to build the clinical evidence needed to bring their combined vision to market. The ultimate goal is to develop powerful AI-driven analytics that generate new insights into complication risk, healing patterns, and surgical quality, creating a new standard for data-driven perioperative care.